Searched for
DAIICHI SANKYO
Daiichi-Ranbaxy case: Delhi HC orders forensic audit into transactions of Fortis, Singh brothersThe Delhi High Court has appointed a forensic auditor to examine transactions. This audit aims to trace the dissipation of Fortis Healthcar...- Delhi HC orders forensic audit of Fortis, IHH and RHT transactions in $4.6-billion Daiichi-Singh caseThe Delhi High Court on Monday ordered the appointment of a forensic auditor to examine transactions involving Fortis Healthcare, Malaysia’...
- Personality rights going out of hand, says Delhi High Court while hearing Janhvi Kapoor's pleaThe Delhi High Court seeks to bring sanity to personality rights, noting the issue is escalating. Justice Anup Jairam Bhambani heard Jahnvi...
- Delhi HC set to rule on Daiichi Sankyo arbitration caseThe Delhi High Court is expected to rule this week on Daiichi Sankyo’s long-running arbitration dispute with former Fortis promoters Malvin...
- Daiichi comments continue to damage interests: IHH UnitNorthern TK Venture, a subsidiary of IHH Healthcare, has increased its legal claim against Daiichi Sankyo. The claim is now for ₹11,800 cro...
- Fortis Open Offer: Daiichi Sankyo's 'misleading' statements continue to damage interests, says NTKIHH Healthcare's subsidiary, NTK, accuses Daiichi Sankyo of damaging its interests through misleading statements regarding the Fortis Healt...
- IHH Healthcare increases damages claim against Daiichi Sankyo to Rs 11,800 cr over Fortis acquisition disputeIHH Healthcare's indirect subsidiary, Northern TK Venture Pte Ltd, has significantly increased its damages claim against Daiichi Sankyo to ...
- IHH Healthcare claims 20 bn yen damages from Daiichi Sankyo for interference in Fortis Healthcare dealNorthern TK Venture Pte Ltd (NTK), a unit of Malaysia-based IHH Healthcare, has filed a lawsuit against Daiichi Sankyo in Tokyo District Co...
- Daiichi Sankyo sells Sun Pharma stake in block deals; stock plungesSun Pharma were under selling pressure and plunged as much as 10.63% in intraday trade as Daiichi Sankyo offloaded its entire stake.
- Ranbaxy, Daiichi Sankyo to collaborate in Brazil to expand businessIn Brazil, Daiichi Sankyo has built up its market presence with innovative pharmaceuticals through Daiichi Sankyo Brazil.
- Ranbaxy, Daiichi Sankyo to leverage synergies in ThailandRanbaxy Laboratories and its Japanese parent Daiichi Sankyo to integrate their business operations in Thailand to maximise synergies.
- Daiichi Sankyo and Ranbaxy Launch hybrid business in VenezuelaDaiichi Sankyo & Ranbaxy announced that Daiichi Sankyo Venezuela would begin marketing Ranbaxy products in Venezuela as part of hybrid busi...
- Ranbaxy laboratories may hand over Latin American operations to Daiichi SankyoRanbaxy may hand over its L American mkting operations to Daiichi Sankyo, a move could be a precursor to the Indian drugmaker's exit from s...
- Daiichi Sankyo reports Q3 net loss of $255 millionDaiichi Sankyo suffered a net loss of $255 million in the Octr-Dec quarter of 2011 due to a strong yen and one-time charges related to Ranb...
- Ranbaxy to sell Daiichi Sankyo product in MalaysiaDrug firm Ranbaxy Laboratories and Japan's Daiichi Sankyo today said Ranbaxy will market its parent company's products in Malaysia.
- Ranbaxy Laboratories to sell Daiichi Sankyo's products in ItalyRanbaxy Laboratories and its parent firm Daiichi Sankyo said they have entered into a partnership to distribute the Japanese firm's product...
- Ranbaxy, Daiichi Sankyo to expand business in MexicoThe two cos will launch Daiichi Sankyo's Olmesartan Medoxomil, used to treat high blood pressure, in Mexico before end of 2011.
- Daiichi to use Ranbaxy network to sell products in SingaporeRanbaxy and Daiichi Sankyo had signed a three-year plan to exploit synergies in operations to enhance their generic as well as branded busi...
- Ranbaxy transfers new drug discovery unit to Daiichi SankyoRanbaxy Laboratories on Friday said it has transferred its new drug discovery research unit (NDDR) to Daiichi Sankyo India Pharma.
- Daiichi Sankyo defers open offer to acquire Zenotech LabsDaiichi Sankyo has deferred the open offer to acquire 20% from public shareholders of Zenotech Labs as it is yet to get the approval from I...
Load More
